“…Using a biotinylated parthenolide analog, previous studies by the lab of Crews established that one of the primary targets that drives the anti-inflammatory and anti-cancer activity of parthenolide is IKK-b wherein cysteine 179 (C179) is modified thus impairing IKK-b and NFkB signaling (Kwok et al, 2001). Additional studies have revealed other direct targets of parthenolide that may help to explain the therapeutic properties of this natural product, including targeting of specific cysteines within heat shock protein Hsp72 and STAT3 downstream signaling targets such as Janus kinases JAK2 (Liu et al, 2018;Shin et al, 2017). Moreover, this natural product has also been shown to affect additional cell signaling pathways including induction of oxidative stress and apoptosis, focal adhesion kinase 1 (FAK1) signaling, HIF-1a signaling, epithelial-to-mesenchymal transition, Wnt/b-catenin signaling, MAPK signaling, and mitochondrial function (Carlisi et al, 2011(Carlisi et al, , 2016Jafari et al, 2018;Kim et al, 2017;Kwok et al, 2001;Lin et al, 2017;Zhang et al, 2017).…”